Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus LARTRUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus LARTRUVO.
FOLOTYN vs LARTRUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Olaratumab is a recombinant human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent